Precede Biosciences raised $83.5 million in Series B financing and a $20 million credit facility to scale its liquid‑biopsy platform for pharma partnerships, focusing on genome‑wide expression of cancer surface proteins measured from blood. The company said the funds will expand capacity to meet growing demand from drug developers. At JP Morgan, Natera highlighted robust Signatera MRD growth—Q4 revenue acceleration, rising ASPs, and plans to roll out an enhanced Signatera that integrates phased and structural variants alongside multimodal models combining ctDNA, pathology imaging and sequencing data in mid‑2026. Natera flagged expected Medicare reimbursement expansions for more cancer types as a revenue driver. Both companies emphasized working with pharma to deploy blood‑based biomarkers for patient selection, response monitoring and combination trial designs, marking continued commercial maturation of liquid biopsy diagnostics.